Tuesday, December 5, 2023
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.
Disclosures for additional planners can be found here.
Professor of Medicine
University of Paris-Saclay
Head
Department of Cancer Medicine
Institut Gustave Roussy
President
Groupe d’Etude des Tumeurs Genito-Urinaires (GETUG)
Villejuif, France
Nurse Practitioner
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin
Hematology/Oncology Clinical Pharmacy Specialist
The University of North Carolina Medical Center
Chapel Hill, North Carolina
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
This educational activity is intended for an international audience of global oncologists, urologists, nurses, nurse practitioners, pharmacists, and other interprofessional healthcare providers who care for individuals with prostate cancer.
The goal of this activity is that physicians, nursing professionals, and pharmacists will be better able to understand the current and emerging approaches with oral antiandrogen therapies in the management of prostate cancer and discuss collaborative approaches to care.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.
Disclosures for additional planners can be found here.
Professor of Medicine
University of Paris-Saclay
Head
Department of Cancer Medicine
Institut Gustave Roussy
President
Groupe d’Etude des Tumeurs Genito-Urinaires (GETUG)
Villejuif, France
Nurse Practitioner
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin
Hematology/Oncology Clinical Pharmacy Specialist
The University of North Carolina Medical Center
Chapel Hill, North Carolina
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.
Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: JA0007105-0000-22-078-H01-P).
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 4/1/2022
Valid for credit through: 4/1/2023, 11:59 PM EST
processing....
A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.
.gif)